WO2012115479A3 - Dérivés de diaminopyrimidine et leurs procédés de préparation - Google Patents

Dérivés de diaminopyrimidine et leurs procédés de préparation Download PDF

Info

Publication number
WO2012115479A3
WO2012115479A3 PCT/KR2012/001425 KR2012001425W WO2012115479A3 WO 2012115479 A3 WO2012115479 A3 WO 2012115479A3 KR 2012001425 W KR2012001425 W KR 2012001425W WO 2012115479 A3 WO2012115479 A3 WO 2012115479A3
Authority
WO
WIPO (PCT)
Prior art keywords
preparation
pharmaceutically acceptable
acceptable salt
processes
diaminopyrimidine derivative
Prior art date
Application number
PCT/KR2012/001425
Other languages
English (en)
Other versions
WO2012115479A2 (fr
Inventor
Jae-Young Sim
Myung-Hun Cha
Tae-Kyun Kim
Hyun-Joo Lee
Young-Ae Yoon
Dong-Hoon Kim
Hee-Jeong AHN
Tai-Au Lee
Kyoung-Kyu AHN
Kwan-Hoon HYUN
Original Assignee
Yuhan Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yuhan Corporation filed Critical Yuhan Corporation
Publication of WO2012115479A2 publication Critical patent/WO2012115479A2/fr
Publication of WO2012115479A3 publication Critical patent/WO2012115479A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne un dérivé de diaminopyrimidine ou son sel pharmaceutiquement acceptable, son procédé de préparation, une composition pharmaceutique le comprenant, et son utilisation. Ledit dérivé de diaminopyrimidine ou son sel pharmaceutiquement acceptable fonctionne en tant qu'agoniste du récepteur 5-HT4, et peut donc être appliqué utilement dans la prévention ou le traitement d'un dysfonctionnement de la motilité gastrointestinale, l'une des maladies gastrointestinales, telles que le reflux gastro-œsophagien pathologique (GERD), la constipation, le syndrome du côlon irritable (IBS), la dyspepsie, l'occlusion intestinale postopératoire, la vidange gastrique retardée, la gastroparésie, la pseudo-occlusion intestinale, le transit retardé d'origine médicamenteuse, ou l'atonie gastrique diabétique.
PCT/KR2012/001425 2011-02-25 2012-02-24 Dérivés de diaminopyrimidine et leurs procédés de préparation WO2012115479A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2011-0016986 2011-02-25
KR1020110016986A KR101682417B1 (ko) 2011-02-25 2011-02-25 다이아미노피리미딘 유도체 및 그의 제조방법

Publications (2)

Publication Number Publication Date
WO2012115479A2 WO2012115479A2 (fr) 2012-08-30
WO2012115479A3 true WO2012115479A3 (fr) 2012-11-01

Family

ID=46721362

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/001425 WO2012115479A2 (fr) 2011-02-25 2012-02-24 Dérivés de diaminopyrimidine et leurs procédés de préparation

Country Status (2)

Country Link
KR (1) KR101682417B1 (fr)
WO (1) WO2012115479A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103896804A (zh) * 2014-04-28 2014-07-02 西安凯立化工有限公司 一种液相催化加氢制备2,5-二氨基苯腈的方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2882158A1 (fr) 2012-08-17 2014-02-20 Cancer Therapeutics Crc Pty Limited Inhibiteurs de vegfr3
EP2885292A4 (fr) 2012-08-17 2015-07-01 Cancer Therapeutics Crc Pty Ltd Inhibiteurs de vegfr3
JPWO2014174745A1 (ja) * 2013-04-26 2017-02-23 国立大学法人京都大学 Ｅｇ５阻害剤
KR101657616B1 (ko) * 2013-05-24 2016-09-19 주식회사유한양행 피리미딘 고리를 포함하는 바이사이클릭 유도체 및 그의 제조방법
CN109153650A (zh) * 2016-04-15 2019-01-04 Epizyme股份有限公司 作为ehmt1和ehmt2抑制剂的胺取代的芳基或杂芳基化合物
AU2018254577B2 (en) 2017-04-21 2024-06-13 Epizyme, Inc. Combination therapies with EHMT2 inhibitors
US20200317642A1 (en) * 2017-10-17 2020-10-08 Epizyme, Inc. Amine-substituted heterocyclic compounds as ehmt2 inhibitors and derivatives thereof
KR102328682B1 (ko) * 2018-08-27 2021-11-18 주식회사 대웅제약 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005011758A2 (fr) * 2003-07-25 2005-02-10 Ciba Specialty Chemicals Holding Inc. Utilisation de 2,4-bis(alkylamino)pyrimidines substituees
WO2008104472A1 (fr) * 2007-02-28 2008-09-04 F. Hoffmann-La Roche Ag Dérivés de 2, 4 -diaminopyrimidine et utilisation de ces derniers comme antagonistes p2x ou comme promédicaments de ceux-ci
US7553840B2 (en) * 2006-12-12 2009-06-30 Lexicon Pharmaceuticals, Inc. 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005011758A2 (fr) * 2003-07-25 2005-02-10 Ciba Specialty Chemicals Holding Inc. Utilisation de 2,4-bis(alkylamino)pyrimidines substituees
US7553840B2 (en) * 2006-12-12 2009-06-30 Lexicon Pharmaceuticals, Inc. 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use
WO2008104472A1 (fr) * 2007-02-28 2008-09-04 F. Hoffmann-La Roche Ag Dérivés de 2, 4 -diaminopyrimidine et utilisation de ces derniers comme antagonistes p2x ou comme promédicaments de ceux-ci

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE PUBCHEMCOMPOUND retrieved from http://pubchem.ncbi.nlm.nih.gov/search/search.cgi accession no. 18645 *
KAMILIA M. AMIN ET AL.: "Design, synthesis and vasorelaxant evaluation of novel coumarin–pyrimidine hybrids", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 19, no. 20, 15 October 2011 (2011-10-15), pages 6087 - 6097 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103896804A (zh) * 2014-04-28 2014-07-02 西安凯立化工有限公司 一种液相催化加氢制备2,5-二氨基苯腈的方法
CN103896804B (zh) * 2014-04-28 2016-03-30 西安凯立新材料股份有限公司 一种液相催化加氢制备2,5-二氨基苯腈的方法

Also Published As

Publication number Publication date
WO2012115479A2 (fr) 2012-08-30
KR20120097649A (ko) 2012-09-05
KR101682417B1 (ko) 2016-12-06

Similar Documents

Publication Publication Date Title
WO2012115478A3 (fr) Dérivés de diaminopyrimidine et leurs procédés de préparation
WO2012115479A3 (fr) Dérivés de diaminopyrimidine et leurs procédés de préparation
WO2006104826A3 (fr) Composes antagonistes du recepteur du glucagon, compositions renfermant de tels composes et methodes d'utilisation
WO2008021849A3 (fr) Nouveaux composés comme antagonistes ou agonistes inverses à des récepteurs d'opioïdes
CL2007002499A1 (es) Sales citrato y tartrato de compuestos derivados de acido pirrolidinilaminoacetilpirrolidinboronico, inhibidores de dpp-iv; metodo de preparacion; forma solida; combinacion farmaceutica, util para el tratamiento de diabetes.
WO2007111864A3 (fr) Composes antagonistes du recepteur du glucagon, compositions contenant de tels composes et procedes d'utilisation
WO2007136577A3 (fr) Composés antagonistes du récepteur du glucagon, compositions contenant ces composés, et procédés d'utilisation
EP3781571C0 (fr) Dérivés de n-[4-oxo-2,3-dihydro-pyrido[3,2-b][1,4]oxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazole-2-carboxamide et composés similaires en tant qu'inhibiteurs de la kinase rip1 pour le traitement p.e. du syndrome de l'intestin irritable (sii)
WO2010040508A8 (fr) Anticorps anti-vegf/anti-ang-2 bispécifiques
WO2008009415A3 (fr) Dérivés hétéroaryliques substitués
IL195514A (en) Converted Pyridyl Compounds
WO2008051942A3 (fr) Agonistes du récepteur farnésoïde x
WO2010146179A3 (fr) Composition pharmaceutique solide comprenant du rivaroxaban
WO2008076243A3 (fr) Composés acyl-bipipéridinyle, compositions contenant de tels composés et procédés de traitement
WO2010062715A3 (fr) Polymorphes de dasatinib et leur procédé de préparation
WO2010001257A3 (fr) Nouvelles formes à l’état solide de laquinimod et son sel de sodium
HK1121453A1 (en) Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-ht2a serotonin receptor 5-ht2a
WO2010052144A3 (fr) Agonistes du récepteur 2 de neuropeptide (y-2r) et leurs utilisations
WO2011045232A3 (fr) Agonistes du récepteur du neuropeptide-2 (y-2r)
WO2010049449A3 (fr) Nouveaux sels de sunitinib
EA201001312A1 (ru) Твердая фармацевтическая композиция, содержащая непептидный антагонист рецептора ангиотензина ii и диуретик
WO2008088779A3 (fr) Formes solides de 5-azacytidine et procédés de préparation de ces dernières
WO2007132354A3 (fr) Procédé de préparation de voriconazole, nouvelle forme polymorphe d'un produit intermédiaire de ce composé et utilisations dudit composé
WO2013175499A3 (fr) Forme polymorphe du 5-(4-[4-(5-cyano-1h-indol-3-yl)butyl]pipérazin-1-yl)benzofurane-2-carboxamide
CL2007003503A1 (es) Compuestos derivados de indol-2-il-carbonil-piperidina-benzoimidazolona y de indol-2-il-carbonil-piperidina-benzoxazolona, antagonistas del receptor de la v1a; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento de dismenorrea

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12748945

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12748945

Country of ref document: EP

Kind code of ref document: A2